See more : Kam Hing International Holdings Limited (2307.HK) Income Statement Analysis – Financial Results
Complete financial analysis of PetIQ, Inc. (PETQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PetIQ, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- IXICO plc (IXI.L) Income Statement Analysis – Financial Results
- Capital One Financial Corporation (COF-PK) Income Statement Analysis – Financial Results
- Just Energy Group Inc. (JENGQ) Income Statement Analysis – Financial Results
- Appian Corporation (APPN) Income Statement Analysis – Financial Results
- Pine Technology Acquisition Corp. (PTOCU) Income Statement Analysis – Financial Results
PetIQ, Inc. (PETQ)
About PetIQ, Inc.
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.10B | 921.51M | 932.53M | 780.05M | 709.43M | 528.61M | 266.69M | 200.16M | 205.69M | 161.49M |
| Cost of Revenue | 849.22M | 711.85M | 746.14M | 644.86M | 602.05M | 445.33M | 215.49M | 167.62M | 166.53M | 139.69M |
| Gross Profit | 252.74M | 209.66M | 186.39M | 135.19M | 107.38M | 83.29M | 51.19M | 32.55M | 39.16M | 21.80M |
| Gross Profit Ratio | 22.94% | 22.75% | 19.99% | 17.33% | 15.14% | 15.76% | 19.20% | 16.26% | 19.04% | 13.50% |
| Research & Development | 1.10M | 2.10M | 8.00M | 2.30M | 1.30M | 203.00K | 514.00K | 310.00K | 380.00K | 1.14M |
| General & Administrative | 146.03M | 162.46M | 170.52M | 138.38M | 103.20M | 72.26M | 37.91M | 31.85M | 35.59M | 23.42M |
| Selling & Marketing | 45.60M | 20.10M | 16.20M | 10.10M | 4.50M | 2.90M | 2.20M | 1.20M | 6.08M | 5.49M |
| SG&A | 191.63M | 182.56M | 170.52M | 138.38M | 103.20M | 72.26M | 37.91M | 31.85M | 35.59M | 28.91M |
| Other Expenses | -160.00K | 130.00K | 1.92M | 571.00K | 172.00K | -345.00K | 201.00K | 666.00K | 0.00 | 0.00 |
| Operating Expenses | 192.73M | 182.56M | 170.52M | 138.38M | 103.20M | 72.26M | 37.91M | 31.85M | 35.59M | 31.81M |
| Cost & Expenses | 1.04B | 894.41M | 916.66M | 783.24M | 705.25M | 517.59M | 253.40M | 199.46M | 202.12M | 171.50M |
| Interest Income | 0.00 | 27.40M | 24.70M | 22.81M | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 980.00K |
| Interest Expense | 34.55M | 27.37M | 24.70M | 26.30M | 14.50M | 8.02M | 1.56M | 3.06M | 3.55M | 0.00 |
| Depreciation & Amortization | 44.57M | 32.62M | 36.67M | 24.88M | 15.14M | 11.90M | 3.40M | 2.98M | 3.14M | 2.30M |
| EBITDA | 81.49M | 12.59M | 48.85M | 22.38M | 12.42M | 19.62M | 16.83M | 2.65M | 4.77M | -5.96M |
| EBITDA Ratio | 9.49% | 6.80% | 6.12% | 3.64% | 2.94% | 4.38% | 6.41% | 2.72% | 3.26% | -3.69% |
| Operating Income | 60.02M | 27.23M | 15.87M | -2.62M | 4.36M | 7.75M | 13.29M | 702.00K | 3.57M | -8.25M |
| Operating Income Ratio | 5.45% | 2.96% | 1.70% | -0.34% | 0.61% | 1.47% | 4.98% | 0.35% | 1.74% | -5.11% |
| Total Other Income/Expenses | -34.71M | -27.24M | -28.39M | -22.13M | -14.47M | -8.32M | -1.50M | -4.10M | -4.92M | -870.00K |
| Income Before Tax | 2.37M | -47.41M | -12.51M | -28.81M | -17.61M | -574.00K | 11.79M | -3.40M | -1.35M | -10.99M |
| Income Before Tax Ratio | 0.21% | -5.14% | -1.34% | -3.69% | -2.48% | -0.11% | 4.42% | -1.70% | -0.66% | -6.81% |
| Income Tax Expense | -173.00K | 1.21M | 3.87M | 52.22M | -3.31M | -661.00K | 3.97M | 3.00K | -1.35M | -6.00K |
| Net Income | 2.13M | -48.62M | -16.38M | -81.02M | -14.30M | -782.00K | -3.49M | -3.40M | -1.35M | -10.99M |
| Net Income Ratio | 0.19% | -5.28% | -1.76% | -10.39% | -2.02% | -0.15% | -1.31% | -1.70% | -0.66% | -6.80% |
| EPS | 0.07 | -1.67 | -0.58 | -3.29 | -0.63 | -0.05 | -0.26 | -0.28 | -0.11 | -0.89 |
| EPS Diluted | 0.07 | -1.67 | -0.58 | -3.29 | -0.63 | -0.05 | -0.26 | -0.28 | -0.11 | -0.89 |
| Weighted Avg Shares Out | 29.14M | 29.16M | 28.24M | 24.63M | 22.65M | 17.22M | 13.22M | 12.29M | 12.29M | 12.29M |
| Weighted Avg Shares Out (Dil) | 29.53M | 29.16M | 28.24M | 24.63M | 22.65M | 17.22M | 13.22M | 12.29M | 12.29M | 12.29M |
PetIQ, Inc. Reports Second Quarter 2024 Financial Results
PetIQ, Inc. to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
3 Pet Stocks That Are Better Buys Than Chewy
Why Fast-paced Mover PetIQ (PETQ) Is a Great Choice for Value Investors
PetIQ, Inc. to Participate in the Oppenheimer 24th Annual Consumer Growth and E-Commerce Conference
Wall Street Analysts See a 40.44% Upside in PetIQ (PETQ): Can the Stock Really Move This High?
Are Investors Undervaluing PetIQ (PETQ) Right Now?
Despite Fast-paced Momentum, PetIQ (PETQ) Is Still a Bargain Stock
Natixis Advisors L.P. Increases Position in PetIQ, Inc. (NASDAQ:PETQ)
PetIQ, Inc. (PETQ) Q1 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports